Evidence map›Paper›PMID 32342603›Full record

ArticleCancer science2020

Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.

Ryo Kazama, Hiroaki Miyoshi, Mai Takeuchi, Kohta Miyawaki, Kazutaka Nakashima, Noriaki Yoshida, Keisuke Kawamoto, Eriko Yanagida, Kyohei Yamada, Takeshi Umeno and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Deciphering the role of CD47 in cancer immunotherapy.Journal of advanced research · 2024
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ryo KazamaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID https://orcid.org/0000-0002-2207-4508
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID https://orcid.org/0000-0002-2356-3725
Mai TakeuchiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.ORCID https://orcid.org/0000-0002-4006-3810
Kohta MiyawakiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kazutaka NakashimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Noriaki YoshidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Keisuke KawamotoDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Eriko YanagidaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kyohei YamadaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takeshi UmenoDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Takaharu SuzukiDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
Masao SetoDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kurume University · JPKyushu University · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interaction between CD47 and signal-regulatory protein-α (SIRPα) inhibits phagocytosis, thus affecting the clinical outcomes of neoplastic diseases. Although CD47 upregulation is associated with poor prognosis in several malignancies, the effect of SIRPα expression and its coexpression with CD47 remains unclear. This study aimed to investigate the clinicopathologic effect of CD47 and SIRPα expression in diffuse large B-cell lymphoma (DLBCL). Immunostaining of 120 biopsy samples showed that CD47 is primarily expressed in tumor cells, whereas SIRPα is expressed in nonneoplastic stromal cells, mostly macrophages. CD47

Indexed as

Signal TransductionAdultAgedAged, 80 and overAntigens, DifferentiationAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCD47 AntigenCyclophosphamideDoxorubicinFemaleGene ExpressionHumansImmunohistochemistryIn Situ HybridizationLymphoma, Large B-Cell, DiffuseAntigens, DifferentiationBiomarkersCD47 AntigenCD47 protein, humanCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolReceptors, ImmunologicRituximabSIRPA protein, humanVincristinehematologyimmunohistochemistrynon-Hodgkin lymphomapathologyprognosis

Identifiers

PMID32342603
PMCPMC7385345
OpenAlexW3017658216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.